Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318409 · ClinicalTrials.gov registry record · Phase 2
Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM
A Phase 2 study, sponsored by San Francisco Department of Public Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00318409 is a Phase 2 study that has completed, run by San Francisco Department of Public Health. The registered enrollment target is 30 participants.
The verdict
NCT00318409, a Phase 2 study, has completed, sponsored by San Francisco Department of Public Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. No studies have tested the feasibility and acceptability of conducting pharmacologic interventions to reduce meth use and meth-associated sexual risk behavior among MSM. The purpose of this pilot study is to determine the feasibility enrolling and retaining meth-dependent MSM into a pharmacologic study of bupropion vs. placebo and measuring the tolerability of and adherence to medication among these participants.
Interventions
- DRUG Placebo
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318409
The ClinicalTrials.gov registry entry for NCT00318409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is San Francisco Department of Public Health, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00318409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318409 about?
NCT00318409 is a clinical study titled "Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM". Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. No studies have tested the feasibility and acceptability of conducting pharmacologic interventions to red...
What is the current status of trial NCT00318409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00318409?
The interventions under investigation include: Placebo (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00318409?
This trial is sponsored by San Francisco Department of Public Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.